Voya Investment Management LLC Lowers Position in OPKO Health, Inc. $OPK

Key Points

• Voya Investment Management LLC reduced its holdings in OPKO Health by 35.5%, selling 445,158 shares in the 1st quarter and ending with a total of 809,876 shares valued at $1,344,000.
• CEO Phillip Frost purchased 675,000 shares at an average price of $1.32, increasing his direct ownership in the company to over 214 million shares valued at approximately $283 million.
• Brokerages have mixed views on OPKO Health, with LADENBURG THALM/SH SH upgrading the stock to a "strong-buy" rating, while Zacks Research shifted its rating from "strong sell" to "hold."

Voya Investment Management LLC reduced its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 35.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 809,876 shares of the biotechnology company's stock after selling 445,158 shares during the quarter. Voya Investment Management LLC owned 0.10% of OPKO Health worth $1,344,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in shares of OPKO Health by 94.7% in the fourth quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company's stock valued at $855,000 after purchasing an additional 282,844 shares during the period. Deutsche Bank AG lifted its position in shares of OPKO Health by 48.3% in the 4th quarter. Deutsche Bank AG now owns 309,867 shares of the biotechnology company's stock worth $456,000 after buying an additional 100,868 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company's stock worth $275,000 after buying an additional 8,064 shares during the last quarter. Millennium Management LLC lifted its position in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock valued at $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in OPKO Health by 42.3% in the 4th quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company's stock valued at $2,106,000 after purchasing an additional 425,484 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the company's stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $1.32 per share, with a total value of $891,000.00. Following the completion of the transaction, the chief executive officer directly owned 214,676,448 shares in the company, valued at $283,372,911.36. This trade represents a 0.32% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 49.69% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on OPK. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research report on Tuesday, July 8th. Zacks Research upgraded shares of OPKO Health from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $2.63.

OPKO Health Price Performance

NASDAQ OPK opened at $1.44 on Tuesday. OPKO Health, Inc. has a 12-month low of $1.11 and a 12-month high of $2.04. The stock has a market capitalization of $1.14 billion, a PE ratio of -5.76 and a beta of 1.40. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The company has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $1.41.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $165.74 million. During the same period in the prior year, the business earned ($0.01) EPS. The company's revenue for the quarter was down 13.9% compared to the same quarter last year. As a group, equities analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OPKO Health, Inc. (NASDAQ:OPK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.